home.aspx
 
EVENTS

Drug Formulation & Analytical Techniques
DRUG FORMULATION & ANALYTICAL TECHNIQUES
December 16-17, 2019
Pharmaceutical formulation in pharmaceutics is the process in which various chemical substances including the vigorous drug are joined to produce a final medicinal product. Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally...

International Conference on Metabolic Diseases and Liver Cancer
INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER
December 16-17, 2019
“INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER ’’ is organized in order to bring light and anticipate to the dark sides of human liver cancer and irregular human metabolic diseases which are prevailing worldwide. This conference is effective on all sides as it giv...

Biorad Medisys Pvt Ltd

Biorad Medisys is a leading global specialty manufacturer of a large portfolio of implants and surgical devices . Full-fledged integrated manufacturing facilities in Pune and Bengaluru, adhering to strict GMP are set up, starting its operations almost a decade ago the company operates under stringent guidelines and certified by ISO 13485/IS0 9001-2008. The facilities boast of state of the art machinery imported from UK, Germany & Japan. The company develops and markets innovative technologies and medical products through its two divisions; Orthovasive and Indovasive which are CE certified and partners with healthcare professionals in enhancing patient care.

RELATED NEWS


Celgene has unveiled a meta-analysis of pooled data from three late-stage studies showing a significant overall survival (OS) benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation (ASCT). The meta-analysis pooled data from 1,208 patients newly diagnosed in multiple myeloma who underwent ASCT in three randomised, controlled Phase III studies (CALGB 100104, IFM 2005-02, GIMEMA RVMM-PI-209). The findings, p...

READ MORE

Roche’s Flatiron Health and the U.S. Food and Drug Administration (FDA)’s Information Exchange and Data Transformation (INFORMED) Program expanded a two-year-old collaboration agreement. The agreement, forged in 2016, has enabled the regulatory agency to gain a better understanding of how real-world-evidence derived from de-identified patient datasets curated from electronic health records, can support regulatory decision-making. Since the agreement was first struck, the FDA and Flat...

READ MORE

AbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukemia (CLL) to be approved by the FDA, its tenth indication. The green light from the US regulator is for a regimen based on BTK inhibitor Imbruvica (ibrutinib) and Roche’s anti-CD20 drug Gazyva (obinutuzumab) in CLL – the most common form of leukemia – as well as a related disease called small lymphocytic lymphoma (SLL). The approval is based on th...

READ MORE

Forty years ago, one of Dr. Stephen Hauser’s first patients was a young Harvard Law School graduate and White House aide with a case of multiple sclerosis that raced like a brush fire through her brain. She quickly lost her ability to speak, swallow, and breathe. She got married in a wheelchair in her hospital room, tethered to breathing and feeding tubes and dressed in her wedding gown....

READ MORE

Verseau Therapeutics has launched to develop immunotherapies that act as checkpoint modulators of macrophages, inducing an immune response against cancer. The company received a $50m investment from 3SBio, 20 / 20 HealthCare Partners, Yonghua Capital, The Mark Foundation for Cancer Research, InHarv Partners, Highlight Capital and Alexandria Venture Investments. Verseau Therapeutics will use the funds to advance macrophage checkpoint modulator (MCM) programmes into the clinic. Macrophages exhibit...

READ MORE

Generic competition is eating away at J&J's prostate cancer empire. Sales of Zytiga (abiraterone acetate) totaled $698 million in the second quarter, reflecting a 23% decline year over year. According to Iqvia data cited by SVB Leerink, J&J held 56% of the abiraterone acetate market for the week ending Sept. 6, a slip from the 63% it held a week prior. Apotex and Mylan, which each launched a generic form of Zytiga over the last year, had market shares of 26% and 16%, respectively. Wh...

READ MORE

EVENTS

Medicinal and Pharmaceutical Chemistry
MEDICINAL AND PHARMACEUTICAL CHEMISTRY
December 16-17, 2019
Medicinal Chemistry is the science of design and chemical synthesis focusing mainly on small organic molecules and their development of pharmaceutical agents, or bio-active molecules (drugs). Pharmaceutical Chemistry is the same plus the science of pharmaceutical and biomedical analysis to the synth...

International Conference on Metabolic Diseases and Liver Cancer
INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER
December 16-17, 2019
“INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER ’’ is organized in order to bring light and anticipate to the dark sides of human liver cancer and irregular human metabolic diseases which are prevailing worldwide. This conference is effective on all sides as it giv...